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Background
Natriuretic peptides increase in heart failure. Atrial
natriuretic peptide (ANP) and brain natriuretic peptide
(BNP) activate the natriuretic peptide receptor (NPR)-A
and C-type natriuretic peptide (CNP) the NPR-B, caus-
ing production of cyclic 3’,5’-guanosine monophosphate
(cGMP). Our group has previously shown that CNP
potentiates b1-adrenoceptor-mediated inotropic response
by increasing cAMP levels. This is explained by a cross-
talk between cGMP and cAMP, where cGMP produced
by NPR-B inhibits phosphodiesterase (PDE) 3 from
degrading cAMP. Increased b1-adrenoceptor signalling
is harmful in heart failure which is the basis for use of
b-blockers in heart failure therapy. Further, PDE3 inhi-
bition has been associated with increased mortality in
heart failure. Thus, an NPR-B antagonist could eliminate
the unwanted effects due to PDE3 inhibition and
increased b1-adrenoceptor signalling by CNP. There are
no selective NPR-B antagonists available, and our aim is
to identify and characterize novel non-peptide small
molecular selective NPR-B antagonists for potential use
in heart failure therapy.
Methods
Small molecular compounds were screened for activity
and selectivity towards NPR-A and NPR-B, using a
cGMP assay based on AlphaScreen technology. Based
on this technology, we can identify compounds that
interfere with BNP- and CNP-stimulated cGMP produc-
tion through the NPR-A and NPR-B receptor, respec-
tively. Antagonism properties can also be characterized.
Results and conclusion
Potential NPR-B antagonists were identified by high
throughput screening of about 20,000 compounds. Hits
were tested against the NPR-A to determine selectivity,
and characterized as non-competitive and reversible
inhibitors of NPR-B response in HEK293 cells, display-
ing properties of negative allosteric modulators [1].
Information on structure and activity relationship (SAR),
was collected and over 50 new compounds, clustered in
five different groups of chemically related compounds,
were designed in silico and were tested for activity and
selectivity towards NPR-A and NPR-B. From this test-
ing, three out of five groups were found interesting. The
ligands with the best antagonistic property from each of
the 3 groups were used to select 60 more compounds
by in silico design for further testing.
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